[Form 4] Harvard Apparatus Regenerative Technology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

He Junli, who serves as Chief Executive Officer and a director of Harvard Apparatus Regenerative Technology, Inc. (HRGN), purchased 11,225 shares of HRGN common stock in transactions executed between September 2, 2025 and September 22, 2025 at a weighted average price of $1.85 per share. Following these purchases the reporting person beneficially owned 277,275 shares. The Form 4 was signed by a power of attorney on September 24, 2025. The filing discloses no derivative transactions and notes the weighted average price reflects multiple trades; the reporting person will supply transaction-level price details on request.

Positive

• Insider purchase by the CEO and director totaling 11,225 shares, which increased direct beneficial ownership to 277,275 shares.
• No derivative transactions were reported, simplifying the ownership picture to straight common stock holdings.

Negative

• Aggregated price disclosure uses a weighted average for purchases between September 2 and September 22, 2025, so individual trade prices are not itemized in the filing.
• Filed by power of attorney rather than signed directly by the reporting person (signature executed by Joseph Damasio).

Insights

Securities Analyst

TL;DR: Insider CEO purchased 11,225 shares at a $1.85 weighted average, increasing direct ownership to 277,275 shares.

The transaction is a straightforward insider purchase by the company's CEO and director, indicating a direct acquisition of common stock with no accompanying derivative activity reported. The disclosed weighted average price and the statement that purchases occurred over a multi-day range are standard for aggregated reporting. For investors, the filing documents an increase in the CEO's direct stake but does not disclose the dollar value of the total holding beyond the per-share price. The filing was executed by power of attorney, which is common for timely SEC submissions.

Corporate Governance Expert

TL;DR: Corporate officer's open-market purchases disclosed; no governance irregularities or disposals reported.

The Form 4 identifies the reporting person as both an officer (CEO) and director and reports only purchases of common stock. The absence of sales, derivative transactions, or transfers in this filing means there are no immediate governance red flags disclosed here. The note that the price is a weighted average and that purchase details can be provided on request is consistent with aggregated reporting practices under Section 16.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

He Junli

(Last) (First) (Middle)

C/O HREGEN

84 OCTOBER HILL ROAD, SUITE 11

(Street)

HOLLISTON MA 01746

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Harvard Apparatus Regenerative Technology, Inc. [ HRGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		P		11,225	A	$1.85(1)	277,275	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from September 2, 2025 to September 22, 2025. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

	/s/ Joseph Damasio by power of attorney	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did HRGN insider He Junli report on Form 4?

The Form 4 reports that He Junli purchased 11,225 shares of HRGN common stock at a weighted average price of $1.85, increasing beneficial ownership to 277,275 shares.

When were the HRGN shares purchased?

The filing states purchases occurred between September 2, 2025 and September 22, 2025, with the Form 4 signed by power of attorney on September 24, 2025.

Does the Form 4 show any derivative transactions for He Junli at HRGN?

No. The Form 4 discloses no derivative securities (options, warrants, or convertible instruments) acquired or disposed of in this filing.

How does the filing report the share price information?

The filing provides a weighted average price of $1.85 and explains this reflects multiple transactions; the reporting person will provide per-trade details on request.

What roles does the reporting person hold at HRGN?

The Form 4 lists the reporting person as both a Director and an Officer (CEO) of Harvard Apparatus Regenerative Technology, Inc.